Onkologie. 2022:16(2):104-106 | DOI: 10.36290/xon.2022.020
Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)
- Pneumologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha
Immunotherapy has become integrated into the standard treatment of patients with advanced NSCLC. There are available different immunotherapy drugs, one of them is nivolumab. Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic NSCLC. Nivolumab as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy in adults. In both cases, nivolumab is for patients without EGFR mutation or ALK translocation. We present a clinical case of a 73 years old patient successfully treated with nivolumab as second-line therapy. She received all 52 cycles of nivolumab monotherapy.
Keywords: advanced NSCLC (non-small cell lung cancer), immunotherapy, nivolumab, second-line treatment, case report.
Published: March 25, 2022 Show citation
References
- SPC OPDIVO [cit. 5.03.2022]. Dostupné z http://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_cs.pdf.
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.
Go to original source... 
Go to PubMed... - Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. Go to original source... Go to PubMed...
- Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1043-1047. Go to original source... Go to PubMed...
- Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. Go to original source... Go to PubMed...